6CM
IMDX

683 Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

683 Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,000
Closed -$95.1K – 211
2026
Q1 		$95.1K Sell
29,000
-48,204
-62% -$280K 0.01% 221
2025
Q4 		$579K Buy
+77,204
New +$436K 0.03% 185

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

683 Capital Management's IMDX Position: Q2 2026 in Review

683 Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2026, closing a stake of 29,000 shares — an estimated $95.1K sold.

683 Capital Management first reported a position in IMDX in Q4 2025 and held it in 2 quarters. The position peaked at $579K in Q4 2025. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • 683 Capital Management reported no remaining Insight Molecular Diagnostics position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 29,000 Insight Molecular Diagnostics shares in Q2 2026, an estimated $95.1K.
  • 683 Capital Management first reported a position in Insight Molecular Diagnostics in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's Insight Molecular Diagnostics position peaked at $579K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.